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Signal Transducers and Activators of Transcription 
(STAT) mediate the signaling downstream of cytokine 
and growth factor receptors, and several of them play a 
role in cancer [1,2]. Once activated by tyrosine-
phosphorylation, STATs form anti-parallel dimers that 
concentrate into the nucleus regulating the expression of 















































growth factors and oncogenes [4], and is constitutively 
tyrosine-phosphorylated in a high percentage of 
tumours and tumour-derived cell lines of both liquid 
and solid origin, where its inhibition often triggers 
growth arrest and/or cell death [1,2,5,6]. Indeed, STAT3 
tyrosine phosphorylation and consequent transcriptional 
activation was shown to be required for cell 
transformation downstream of several oncogenes, the 



























cell  lines.  As  a  result,  cells  are  protected  from  apoptosis  and  senescence  while  becoming  highly  sensitive  to  glucose
deprivation. We show that enhanced glycolysis is dependent on HIF‐1α up‐regulation, while reduced mitochondrial activity
is HIF‐1α‐independent and  likely caused by STAT3‐mediated down‐regulation of mitochondrial proteins. The  induction of
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gene expression signature is mostly consistent with 
tumour cell survival and proliferation [9,10], it varies in 
different tumour types, and a core activity determining 
addiction to STAT3 by a wide spectrum of biologically 
distinct tumors has not yet been identified [9]. In addition 
to its canonical nuclear functions, which require tyrosine 
phosphorylation, DNA binding and transcriptional 
activity, STAT3 was also reported to exert non-nuclear 
functions. In particular, it was shown to localize to 
mitochondria, where it regulates cellular respiration via a 
yet uncharacterized mechanism [11]. Moreover, we have 
recently shown that mitochondrial localization requires 
Serine 727 but not nuclear translocation, DNA binding or 
tyrosine phosphorylation [12]. This activity, rather than 
canonical activation, is required for RAS-dependent 
oncogenic transformation. Thus, STAT3 exerts a central 
role in mediating tumoural transformation downstream of 
many different oncogenes and growth factors, via both its 
canonical transcriptional functions and its non-canonical, 
non-nuclear activities. 
 
Most tumour cells share the peculiar feature of 
switching their metabolism towards aerobic glycolysis, 
i.e. they increase glycolysis and decrease oxidative 
phosphorylation even in conditions of high oxygen 
tension [13-15]. This phenomenon, known as the 
Warburg effect, is thought to lend a metabolic 
advantage to highly proliferating cells when nutrient 
supply is not limiting, as it favours the synthesis of 
essential cellular components required for fast cell 
duplication. Moreover, pre-adaptation to a glycolytic 
metabolism is thought to represent an advantage for 
solid tumours [16], which are often exposed to 
fluctuating oxygen tension, and reduced cellular 
respiration may result in lower production of ROS and 
protection from apoptosis [16-18]. Accordingly, 
strongly glycolytic tumour cells are critically dependent 
on glucose, and glycolysis inhibitors have been 
explored for therapy [19]. The oxygen sensor HIF-1α is 
a highly unstable protein that becomes stabilized under 
hypoxia, leading to the activation of glycolysis and the 
down-regulation of mitochondrial respiration [20,21]. 
HIF-1α protein level is also increased under normoxia 
downstream of oncogenes and growth factor receptors 
via mTor-mediated induction of protein translation, 
which is known to occur downstream of PI3K activation 
[22,23], and indeed increased HIF-1α activity is 
recognized as a major factor contributing to the 
Warburg effect [21,24-26]. Interestingly, several reports 
have linked HIF-1α induction with STAT3 activation, 
proposing either a post-translational or a transcriptional 
mechanism [27-29]. In particular, H. Yu and co-authors 
have recently shown that STAT3 activity is required for 
the hypoxia-induced increase of HIF-1α protein levels 
downstream of an activated Src oncogene, acting at the 
level of promoter transcription [28]. 
 
We have recently generated knock-in mice expressing 
physiological levels of the constitutively active STAT3C 
mutant form [30], and shown its in vivo oncogenic 
potential [31]. In this work we report the analysis of 
primary mouse embryonic fibroblasts (MEF) derived 
from Stat3C/C or WT/WT embryos. Stat3C/C cells show an 
HIF-1α-dependent increased glycolysis and an HIF-1α-
independent reduction in mitochondrial respiration. This 
metabolic switch allows cells to proliferate faster and to 
be protected from apoptotic and senescence stimuli while 
becoming highly sensitive to glucose deprivation. Impor-
tantly, we can show that STAT3 plays an important role 
as a master metabolic regulator also in STAT3-dependent 
human cancer cell lines, offering new insights into its 




STAT3 constitutive activation elicits pre-oncogenic 
features in Stat3C/C MEFs 
 
We have previously shown that STAT3C displays 
increased nuclear localization, prolonged activation and 
enhanced transcriptional activity as compared to the 
wild-type molecule in MEFs, liver and mammary 
tumour-derived cells [31]. We confirmed increased 
localization to the nucleus by immunofluorescence 
(Figure 1A). Compared to the wild type protein, 
STAT3C also displays prolonged tyrosine-phospho-
rylation upon IL-6 treatment, as shown by the enhanced 
nuclear signal of the phosphorylated form detected 24 
and 48 hours after stimulation. Stat3C/C cells grow faster 
than their wild type controls (Figure 1B) and display an 
accelerated cell cycle, observed as a more rapid transit 
through S-phase (Supplementary Figure S1A). Even 
though growing as a monolayer, they reach higher cell 
density at confluence (Figure 1B and 1D, phase contrast) 
and they are highly resistant to apoptosis induced by 
treatment with H2O2 (Figure 1C), starvation, menadione 
or UV irradiation (Supplementary Figure S1B-E). 
Moreover, spontaneous senescence is strongly delayed, 
as shown by beta-galactosidase staining three and six 
weeks post-confluence (Figure 1D). While by six weeks 
all Stat3WT/WT cells were dead, Stat3C/C cells started to 
show beta-gal positivity but were able to survive and 
resume proliferation if passaged (MD, unpublished 
observation). We then assessed the production of 
Reactive Oxygen Species (ROS). While ROS 
accumulation progressively increased with passages in 
the Stat3WT/WT cells, it remained constant in the Stat3C/C 
cells (Figure 1E). The consequently reduced oxidative 
stress may account at least partly for the observed 
resistance to senescence and apoptosis. 
  













































Differential gene expression in the Stat3C/C and 
Stat3WT/WT MEFs 
 
Gene expression profiling revealed about 1000 
differentially expressed genes that were organized 
according to Gene Ontology (GO) annotations (Figure 
2A, B). Stat3C/C MEFs showed significant up-regulation 
of genes included in GO categories related to known 
STAT3 functions such as immune regulation, cell 
adhesion, response to wounding and growth factor bind-













































were more represented, and many of them belonged to 
GO categories related to mitochondrial function (Figure 
2B, D and Supplementary Figure S2). Conversely, 
several genes involved in glycolysis were highly 
expressed in the Stat3C/C cells including pyruvate 
dehydrogenase kinase-1 (Pdk-1). PDK-1 is a key 
glycolysis regulator that acts by inactivating the 
mitochondrial pyruvate dehydrogenase (PDH) complex 
[24], thus limiting the amount of pyruvate entering the 
citric acid cycle (Figure 2C).  
Figure 1. Phenotype of the Stat3C/C MEFs. Primary MEFs were derived from Stat3C/C or Stat3WT/WT embryos and experiments performed
on at  least  three  independent samples per genotype.  (A) Constitutive nuclear  localization of STAT3C. Cells of  the  indicated genotypes

























































































































Ontology functional categories  in the  lists of genes up‐ (A) and down‐regulated (B)  in the Stat3C/C versus the StatWT/WT cells are shown.





independent  embryos  per  genotype.  (C)  OSM‐R,  oncostatin M  receptor;  PDGF‐Ra,  platelet‐derived  growth  factor  receptor;  SOCS3,
Suppressor of Cytokine Signaling‐3; PDK‐1, pyruvate dehydrogenase kinase‐1. (D) ATP‐5L, ATP synthase, H+ transporting, mitochondrial
F0  complex,  subunit G; FH,  fumarate hydratase; NDUFB4, NADH dehydrogenase  (ubiquinone) 1 beta  subcomplex  subunit 4; NDUFA6,
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 6. *, p ≤ 0,01. Empty bars or filled bars, Stat3WT/WT or Stat3C/C MEFs.  
  


















































Stat3C/C MEFs display features of aerobic glycolysis 
 
In agreement with the observed Pdk-1 up-regulation, 
PDH activity in Stat3C/C cells was reduced by about 
50% (Figure 3A). Pdk-1 is a known target of the 


















































can be transcriptionally induced by STAT3 [27]. 
Indeed, Stat3C/C MEFs show significantly increased Hif-
1α mRNA expression (Figure 3B). HIF-1α protein 
levels were also elevated, as shown by immuno-
precipitation of whole cell extracts with anti-HIF-1α 
antibodies followed by Western blot (Figure 3C). 
Figure  3.  Glycolytic metabolism  of  Stat3C/C MEFs.  The  histograms  represent mean  values  ±  s.e.m.  of  three  independent 
experiments. Empty bars or filled bars, Stat3WT/WT or Stat3C/C MEFs respectively. *, p < 0,01. (A) Histograms show the pyruvate 
dehydrogenase  (PDH)  activity  expressed  as  percentage  of  that  detected  in  the  Stat3WT/WT  MEFs.  (B)  Taqman  RT‐PCR 
quantification of HIF‐1α, hypoxia‐inducible  factor‐1α; GLUT‐1,  glucose  transporter‐1; PFK‐L, phospho‐fruktokinase‐liver  type; 
ENO‐1,  enolase‐1.  (C,D)  HIF‐1α  protein  quantification.  (C)  Immuno‐precipitation  followed  by Western  blot  of  total  protein 
extracts with anti‐HIF‐1α antibodies. ACTIN was quantified in the total extracts as a loading control. The numbers at the top of 
the  lanes represent the quantification of the HIF‐1α‐specific signals upon normalization to  IgGs.  (D) Western blot. Cells were 
treated or not with Cobalt Chloride (CoCl2) for 4 hours and nuclear protein extracts were stained for HIF‐1α and ACTIN as an 
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Accordingly, we also detected up-regulation of several 
known HIF-1α target genes [21] such as the glucose 
transporter Glut-1 and  two key  glycolytic enzymes, 
phospho-fruktokinase L-type (Pfk-L) and enolase-1 
(Eno-1) (Figure 3B).  In agreement with the observed 
increased expression of HIF1-α and of several of its 
targets encoding proteins involved in glycolysis, 
Stat3C/C cells exhibit a glycolytic phenotype, producing 















































their glucose intake (Figure 3F). Accordingly, they are 
highly sensitive to glucose deprivation as compared to 
their wild type controls, as shown both by cultivating 
cells in glucose-free medium (Figure 3G) and by 
treating them with 2-Deoxy-D-glucose (2-DG), a 
glucose analogue that inhibits glycolysis [19] (Figure 
3H). These features are highly reminiscent of the well-
known Warburg effect, or aerobic glycolysis, shared by 

















































MEFs of  the  indicated genotypes were  transduced with a mitochondria‐targeted aequorin  (AEQ), which was measured  then
upon challenging with 100 μM ATP as  indicated.  (B) ATP–induced changes  in ATP concentration  in mitochondria. MEFs were
transiently transfected with a mitochondria‐targeted  luciferase 36 hours prior to ATP measurement, and data expressed as a
percentage of the  initial value. (A,B) Data are representative of at  least 10 traces, each from 3  independent experiments. (C)
Respiratory chain activity measured with resazurine. *, p < 0.01 (n=6). (D) Maximal respiratory chain activity, measured with the
use of resazurine in the presence of 300nM FCCP. *, p < 0.01 (n=6). (E) Mitochondrial membrane potential. *, p < 0.05 (n=9). (C‐
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Reduced mitochondrial activity in Stat3C/C MEFs 
 
Cancer cells displaying aerobic glycolysis also co-
ordinately down-regulate cellular respiration, although 
the mechanism is not entirely clear [33]. The significant 
down-regulation of nuclear-encoded genes involved in 
mitochondrial function observed in the Stat3C/C MEFs 
(Supplementary Figure S2), together with their 
decreased PDH activity (Figure 3A), may lead to the 
reduction of mitochondrial respiration. In order to 
assess this, we decided to compare mitochondrial-
specific Ca2+ uptake and mitochondrial ATP production 
in the Stat3C/C and Stat3WT/WT cells. It is indeed well 
known that the mitochondrial membrane potential acts 
as the driving force for the transporter responsible for 
mitochondrial Ca2+ uptake [34]. Inhibition of the 
respiratory chain, which in turn reduces the 
mitochondrial membrane potential, abolishes the ability 
of mitochondria to accumulate Ca2+, making Ca2+ influx 
a well accepted measure of mitochondrial activity [35-
37]. Stat3C/C MEFs showed reduced Ca2+ uptake upon 
ATP stimulation (Figure 4A). Accordingly, both mito-

































activity were reduced in the Stat3C/C MEFs (Figure 4B, 
C). This correlated with lowered maximal respiratory 
chain activity (measured in the uncoupled state) and 
slightly reduced mitochondrial membrane potential 
(Figure 4D, E), which in turn may explain the 
diminished ROS production observed in the Stat3C/C 
MEFs (see Figure 1E). Moreover, in agreement with the 
microarray data, the protein levels of representative 
components of the Electron Transport Chain (ETC), 
particularly those belonging to complexes IV and V, 
were reduced in the Stat3C/C cells (Figure 4G). Taken 
together, these data demonstrate that Stat3C/C MEFs 
feature a reduction of their mitochondrial metabolism, 
caused at least in part by the lower expression of ETC 
components. Despite their lower ATP production, 
Stat3C/C cells show an increased ATP:ADP ratio (Figure 
4F), suggesting a favourable energy balance similar to 
that observed in glycolytic tumour cells and able to 
support their increased proliferation rates. It could be 
argued that the STAT3C mutant might display defective 
mitochondrial functions, which in turn may affect 
mitochondrial activity in the Stat3C/C MEFs. Several 

































Figure 5. STAT3‐mitochondrial  localization and mitochondria morphology. (A)  Intracellular  localization of Stat3.
Sub‐cellular  fractions were  isolated  and  protein  extracts were  prepared  as  described  in M&M. Western  blot
analysis was performed using antibodies against STAT3, and VDAC‐1 or β‐TUBULIN were used as mitochondrial
and  cytoplasmic  markers,  respectively.  Tot,  whole  unfractionated  extract;  Cyto,  cytoplasmic  fraction;  Mito,
mitochondrial  fraction.  (B)  Effects  of  expressing  a  mitochondria  targeted  STAT3  form  (MTS‐Stat3)  on
mitochondrial Ca2+ homeostasis. MEFs were co‐transfected with mitochondria‐targeted aequorin (AEQ) and MTS‐
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chondrial functions are unaffected, and thus that the 
reduced mitochondrial activity of the Stat3C/C MEFs is 
likely a direct effect of STAT3C constitutive transcript-
tional activity. First, the mitochondrial localization of 
STAT3C was indistinguishable from that of the wild type 
protein, as shown by fractionation experiments (Figure 
5A). Second, ectopic expression of mitochondria-targeted 
STAT3 (MTS-STAT3), which normalized the defective 
respiration of RAS-transformed Stat3-/- MEFs [12], could 
not rescue mitochondrial Ca2+-uptake in the Stat3C/C 
MEFs (Figure 5B). Finally, both mitochondrial 
morphology and mass were normal in the Stat3C/C MEFs 
(Figure 5C and not shown), as were the levels of Hif-1α, 
Pdk-1 and lactate in Stat3-/- MEFs (Supplementary Figure 
S3D, E). Since neither nuclear nor mitochondrial STAT3 
are required to maintain basal glucose metabolism and 
HIF-1α levels, the observed mitochondrial phenotype 
cannot be caused by a defective mitochondrial or nuclear 




































Hif-1α is responsible for the induction of aerobic 
glycolysis but not for the reduced mitochondrial 
activity of Stat3C/C cells 
 
The up-regulation of HIF-1α  observed in the Stat3C/C 
cells appears to occur mainly via increased expression 
rather than protein stabilization, since treatment with the 
iron chelator CoCl2, which blocks HIF-1α degradation, 
triggered much higher protein accumulation in the 
Stat3C/C cells than in the wild type counterparts (Figure 
3D). Another well-known mechanism of HIF-1α 
induction is the mTOR-dependent enhanced translation 
occurring downstream of PI3K activation [22,23]. PI3K 
did not however appear to be involved in this context, 
since its inhibition could not affect either the expression 
of Hif-1α and Pdk-1, or the production of lactate 
(Supplementary Figure S3A-C). Therefore, STAT3-
mediated induction of Hif-1α mRNA levels seems to 
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Interestingly, the silencing of Hif-1α normalized the 
glycolytic metabolism of Stat3C/C MEFs, down-
regulating Pdk-1, Glut-1, Pfk-L and Eno-1 mRNAs but 
not the glycolysis-unrelated STAT3 target Socs3 
(Figure 6A). Accordingly, lactate production, glucose 
intake and sensitivity to glucose deprivation were 
significantly reduced (Figure 6B-D). The expression of 
STAT3C, which mimics the constitutive STAT3 
activation observed in many tumours, is thus sufficient 
to promote aerobic glycolysis, acting at least in part 
through transcriptional induction of Hif-1α. Of note, 
Hif-1α silencing lowered the expression levels of the 
Hif-1α target genes as well as the production of lactate 
and of glucose intake also in the Stat3WT/WT MEFs, 
suggesting that Hif-1α plays a role in promoting basal 







































In contrast to the glycolytic metabolism, which was 
entirely dependent on Hif-1α, the mitochondrial Ca2+-
uptake by Stat3C/C cells was completely unaffected by 
Hif-1α silencing and consequent Pdk-1 down-regulation 
(Figure 6E and data not shown). Additionally, the 
silencing of Hif-1α could not rescue the expression of 
nuclear genes encoding for mitochondrial proteins 
(Supplementary Figure S2B). These data clearly 
demonstrate that the up-regulation of glycolysis and the 
down-regulation of mitochondrial function of Stat3C/C 
MEFs, both mediated by constitutively transcriptionally 
active STAT3, occur via independent pathways. The 
leading cause of reduced mitochondrial activity appears 
to be the STAT3-mediated down-regulation of nuclear 
genes encoding for mitochondrial proteins, mirrored by 










































or  silenced  for  HIF‐1α,  as  indicated.  Data  are  shown  as  mean  values  ±  s.e.m.  of  three  independent  experiments.  *,  p  ≤  0,001.  (B)  The
mitochondrial Ca2+ response was assessed as described  in the  legend to Figure 4,  in cells either treated or not with S3I for 12 hours. (C) STAT3
sub‐cellular localization was assessed as described in the legend to Figure 5. (D) Tumour 18F‐FDG uptake. Mice were inoculated with MDA‐MB468
cells and  tumours  let grow up  to 60 mm3 prior to S3I and 18F‐FDG    treatment.  Images were acquired at  the  indicated  times after  the  first S3I
treatment. Shown are coronal  section of  tumour of one  (out of  five) S3I‐treated  (8 days) and one  (out of  three) control mice. Yellow arrows
indicate the tumours. (E) The upper graph represents the variation of glucose uptake normalized over tumour size at the  indicated times after
starting S3I treatment. % of 18F‐FDG uptake= (Suvd=n ‐ Suvd=0)*100/ Suvd=0. The lower graph represents the mean tumour volume ± s.e.m. at the
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STAT3-addicted tumour cell lines undergo STAT3-
dependent aerobic glycolysis 
 
Our data suggest that constitutively active STAT3 can 
act as a central mediator of aerobic glycolysis, which 
would explain the general STAT3 addiction of cancer 
cells. To test this idea, we assessed the effects of 
inhibiting STAT3 on the glycolytic metabolism and 
mitochondrial activity of three STAT3-dependent 
epithelial tumour cell lines, MDA-MB468, SKBR3 and 
DU145, all of which display constitutively active 
STAT3 [38]. Inhibition of STAT3 activity with the S3I 
compound [2], which interferes with the STAT3 SH2 
domain and consequently with STAT3 tyrosine 
phosphorylation and transcriptional activity, causes 
massive apoptosis after 24 hours, but 12 hours treatment 
is sufficient to strongly down-regulate constitutive 
STAT3 phosphorylation avoiding cell death 
(Supplementary Figure S4A, B). In all cell lines, 12 
hours S3I treatment dramatically lowered Hif-1α and 
Pdk-1 expression and decreased lactate production 
(Figure 7A and Supplementary Figure S4B, C), at the 
same time rescuing mitochondrial-Ca2+ uptake (Figure 
7B and Supplementary Figure S4B, C). As expected, 
mitochondrial STAT3 localization, known to be 
independent of tyrosine phosphorylation, was not 
modified (Figure 7C). Gene expression, lactate 
production and mitochondrial-Ca2+ uptake were 
completely unaffected by STAT3 inhibition in T47D 
cells, which do not display constitutively active STAT3 
and are insensitive to STAT3 inhibition (Supplementary 
Figure S4A, D). Thus, tumour cell lines with 
constitutive STAT3 phosphorylation and dependent on 
STAT3 for survival exhibit a strictly STAT3–dependent 
aerobic glycolytic phenotype, comparable to that 
observed in the Stat3C/C MEFs.  
 
Similar to what observed in the Stat3C/C MEFs, Hif-1α 
silencing down-regulated Pdk-1 expression and lactate 
production but not mitochondrial-Ca2+ uptake in MDA-
MB468 cells (Figure 7A and data not shown), suggesting 
that also wild type STAT3, when constitutively activated 
in cancer, can induce aerobic glycolysis via both HIF-1α-
dependent and –independent mechanisms.  
 
STAT3-dependent glycolysis also occurs in vivo 
 
To confirm the fundamental role of STAT3 in 
regulating the glycolytic switch of STAT3-dependent 
tumour cells in vivo, glucose uptake by xenografted 
MDA-MB468 tumours was measured in the presence or 
absence of the S3I treatment by means of PET analysis 
using the radioactive glucose-analogue 18F-FDG (PET-
FDG, Figure 7D). Treatment was started when the 
tumours had reached the volume of 80 mm3 (day 0). 
The tumours of control mice displayed higher increase 
in glucose uptake than in tumour volume, as shown by 
the sharply enhanced FDG signal even upon 
normalization to tumour size (Figure 7E, upper panel). 
In contrast, tumour growth was arrested and glucose 
uptake reduced upon S3I treatment already at 3 days 
(Figure 7E), suggesting that inhibition of STAT3 
activity has prominent effects on glucose metabolism 
also in vivo. Interestingly, treatment of MDA-MB468 
cells with a combination of S3I and 2-DG at sub-
optimal doses yielded cooperative effects on cell 
apoptosis, suggesting the potential therapeutic 
advantage of combining glucose deprivation and 




Most cancer cells share the feature of metabolizing 
glucose by aerobic glycolysis –the Warburg effect- and 
the inducible α subunit of the HIF-1 transcription factor 
lies at the crossroad of both anaerobic and aerobic 
glycolysis [26]. Indeed, HIF-1α induces all know 
glycolysis-related genes while down-regulating 
mitochondrial activity via PDK-1 [21]. HIF-1α activity 
is thought to be controlled mainly at the protein level, 
being highly unstable under normal oxygen tension 
since it is continuously synthesized and then modified 
via prolyl hydroxylation followed by von-Hippel-
Lindau (VHL)-mediated proteasomal degrada-tion [39]. 
Hypoxic conditions decrease the activity of prolyl 
hydroxylases (PHDs), thus inhibiting the interaction 
with VHL and resulting in protein stabilization [40]. On 
the other hand, growth factors and oncogenes can also 
increase HIF-1α activity via enhanced protein 
translation mediated by PI3K-induced mTOR [22,23]. 
STAT3 has been proposed to contribute to HIF-1α 
protein stabilization either via Akt activation [27] or via 
interaction with VHL and consequent inhibition of 
VHL-HIF-1α interaction [29]. Recently, however, 
STAT3 was shown to enhance HIF-1α RNA 
transcription under hypoxia, since it was required to 
mediate HIF-1α up-regulation (both protein and RNA) 
upon hypoxic stimulation of v-Src-transformed cells, 
and was able to bind to the Hif-1α promoter [28]. For 
the first time we show here that even under normoxia 
STAT3 constitutive transcriptional activity is sufficient 
to induce a two-fold increase in Hif-1α mRNA levels, 
in turn resulting in similarly higher protein levels. The 
need for constitutive activation is built into the intrinsic 
instability of the HIF-1α sensor, and is likely to 
represent an important functional difference between 
acute and constitutive STAT3 activity. As mentioned in 
the results section (Figure 3D and Supplementary 
Figure S3A-C), neither protein stabilization nor PI3K-
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mediated translation enhancement appear to play a role 
in the higher HIF-1α levels detected in the Stat3C/C 
MEFs. This relatively low HIF-1α induction is 
sufficient (and necessary, as shown by the silencing 
experiments) to drive a metabolic switch to aerobic 
glycolysis, i.e. the Warburg effect. Interestingly, while 
under hypoxic conditions HIF-1α actively down-
regulates mitochondrial activity via PDK-1 induction, 
the increase in PDK-1 detected in the Stat3C/C MEFs is 
not apparently involved in their reduced mitochondrial 
activity, which cannot be rescued by Pdk-1 
normalization upon Hif-1α silencing. Thus, as depicted 
in Figure 8, constitutive STAT3 activity, occurring in a 
wide variety of tumours downstream of many 
oncogenic signals, is sufficient to determine the switch 
to aerobic glycolysis via two distinct nuclear 







































which in turn up-regulates genes involved in glycolysis. 
This allows fast proliferation and highly increases 
glucose consumption, leading to glucose dependence, 
just like all known glycolytic cancer cells; ii) the down-
regulation of mitochondrial activity, which is HIF-1α- 
and PDK-1-independent and apparently caused by the 
STAT3-mediated reduced expression of many nuclear 
genes encoding for mitochondrial proteins, leading to 
reduced levels of ETC components. At present, we do 
not know if this is due to a direct effect of STAT3 on 
their transcription, or, more likely, to the indirect 
regulation of a common repressor or a targeting 
microRNA(s). The reduced mitochondrial activity may 
contribute to the decreased ROS accumulation observed 
in the Stat3C/C MEFs, which in turn is likely to trigger 
the high resistance of these cells to apoptosis and 








































oncogenic  signals  can  trigger  the  constitutive  activation of  STAT3, either directly or  indirectly. Activated  STAT3 migrates  into  the
nucleus, where  it up‐regulates HIF‐1α expression and  lowers  the expression of mitochondrial mRNAs, either via direct or  indirect
mechanisms. HIF‐1α induces the transcription of different genes involved in glycolysis; the glucose channel GLUT‐1 enhances glucose
intake; the kinase PDK‐1 reduces the conversion of pyruvate  into Acetyl‐CoA,  favouring  its catabolism  into  lactate; other enzymes,
such  as  ENO‐1  or  PFK‐L,  sustain  glycolysis  by  improving  glucose  metabolism.  Increased  glycolysis  results  in  enhanced  lactate
production,  and  allows  the  cell  to maintain  a high ATP/ADP  ratio even  in  the presence of  reduced mitochondrial  respiration. All
together,  this  results  in  enhanced  proliferative  potential.  The  decreased mitochondrial  activity,  insensitive  to HIF‐1α  silencing,  is
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STAT3 emerges as a central player in determining the 
switch to aerobic glycolysis, and this in turn can explain 
why so many biologically distinct tumours are addicted 
to its activity for continuous survival and growth even 
though sometimes do not strictly require it for 
transformation [41]. It is indeed well known that tumour 
cells displaying the Warburg effect become addicted to 
high glucose influxes, and that enhancing aerobic 
glycolysis can favour tumoural transformation. This 
idea is corroborated by the observation that several 
tumour cell lines previously shown to be strictly 
STAT3-dependent present a phenotype super-imposable 
to that of the Stat3C/C MEFs, with high glycolysis levels 
and low mitochondrial respiration, both mediated by 
STAT3 transcriptional activity. Indeed in these cells, 
but not in similar cells not displaying constitutive 
STAT3 activation and accordingly independent of 
STAT3 for survival, inhibition of STAT3 activity 
normalizes glycolysis prior to leading to apoptotic cell 
death, suggesting that STAT3 addiction is at least partly 
linked to STAT3-induced aerobic glycolysis. Exactly as 
observed in the Stat3C/C MEFs, while enhanced 
glycolysis is dependent on HIF-1α, mitochondrial 
respiration is unaffected by HIF-1α silencing. 
Importantly, the observation that treatment with the S3I 
STAT3 inhibitor lowers glucose uptake by tumours 
prior to arresting their growth, suggests that a similar 
mechanism for STAT3 addiction occurs in vivo as well. 
It is puzzling why cancer cells should specifically 
become dependent on STAT3 for aerobic glycolysis, 
since most STAT3-activating oncogenic signals can 
also activate PI3K, a known mediator of this 
phenomenon. Possibly, STAT3 activity is more 
specific/less dispensable since it can at the same time 
regulate glycolysis and mitochondria. Alternatively, 
even when not the only factor inducing the Warburg 
effect, its contribution may nevertheless be crucial. 
Further studies will be required to clarify this issue. 
 
Taken together with the metabolic role of mitochondrial 
STAT3 recently reported by us and others [11,12], 
STAT3 emerges as a central regulator of cell 
metabolism in both transformed and non-transformed 
cells, acting both in the nucleus and in mitochondria.  In 
the nucleus, as shown here, STAT3 constitutive 
activation/tyrosine phosphorylation, which is known to 
occur downstream of many oncogenic pathways, 
promotes aerobic glycolysis and reduces mitochondrial 
respiration without affecting mitochondrial mass or 
morphology. This activity is likely to account for the 
addiction to STAT3 observed in many tumours, 
displaying a variety of abnormally activated oncogenic 
pathways that share the ability to induce STAT3 
tyrosine phosphorylation and aerobic glycolysis. In 
contrast to its nuclear counterpart, mitochondrially 
localized STAT3 is not phosphorylated on tyrosine 705, 
the hallmark of transcriptional activation, but on Serine 
727, promoting oxidative phosphorylation in both non 
transformed pro-B cells [11] and Ras-transformed MEF 
cells [12]. Moreover, it favours aerobic glycolysis 
downstream of Ras oncogenes, which trigger Serine-
STAT3 phosphorylation, and this activity is required for 
Ras-mediated transformation [12]. Although the roles 
played by nuclear or mitochondrial STAT3 may seem 
contradictory, it must be borne in mind that specific 
phosphorylation on tyrosine or serine occurs upon 
distinct stimuli and under distinct physiological or 
pathological conditions, leading to two functionally 
distinct molecules. Our results suggest indeed that it 
will be important to distinguish between the nuclear and 
mitochondrial actions of STAT3 when designing 
STAT3 inhibitors for therapeutic applications.  
 
We propose that this central metabolic role played at 
multiple levels may be at the core of the addiction for 
STAT3 shown by so many biologically different 
tumours. In addition, it may also contribute to the 
protective role described for this factor in tissue damage 
following ischemia-reperfusion or heart infarction 
[42,43].  
 
Finally, our data suggest that a combination of STAT3 
inhibition with glucose deprivation may represent a 
valuable therapeutic strategy in cancer, providing a 
mean to hit fundamental metabolic functions of a wide 
variety of STAT3-dependent, highly glycolytic tumours 




Mice, MEFs preparation and culture, cell lines and 
treatments. Stat3C/C mice [31] were maintained in the 
transgenic unit of the Molecular Biotechnology Center 
(University of Turin). Procedures were conducted in 
conformity with national and international laws and 
policies as approved by the Faculty Ethical Committee. 
Embryos were dissected 13.5 days post coitum for MEF 
derivation. Primary MEFs, 3T3 MEFs [44], MDA-
MB468 and SKBR3 cells (ATCC, Manassas VA, USA) 
were grown in DMEM with GLUTAMAX (Dulbecco’s 
modified Eagle medium; Gibco-BRL, Carlsbad CA, 
USA), DU145 (ATCC) were grown in RPMI 1360 
(Gibco-BRL). Both media were supplemented with 10% 
(v/v) heat-inactivated FCS (fetal calf serum; Gibco-
BRL), 100 U/ml penicillin, 100 µg/ml streptomycin. 
Treatments: S3I-201 inhibitor [2], 100 μM (optimal dose) 
or 50 μM (sub-optimal dose) in DMSO for 12 and 24 
hours; Cobaltous chloride hexahydrate (Sigma Aldrich, 
St. Louis MO, USA), 500 μM for 4 hours; Ly294002 
PI3-K inhibitor, 40 μM for 48 hours. 
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Proliferation rate and cell cycle analysis. For 
proliferation rate, 1.5*105 cells were seeded in 6-well 
plates and counted at the indicated times using the 
Countess Automated Cell Culture (Invitrogen, Carlsbad 
CA, USA). 
 
For cell cycle analysis, sub-confluent cells were starved 
24h hours, re-stimulated with 10% FCS, detached and 
stained with propidium iodide solution (2.5 mg/ml PI 
(Sigma Aldrich), 0.1 mg/ml RNaseA, 0.05% Triton X-
100) at the indicated times, followed by flow cytometry 
analysis. 
 
In vitro cell death, senescence and ROS production. 
Cell death: cells were treated with Menadione (Sigma 
Aldrich, 7.5 μM for 24 hours), H2O2 (Sigma Aldrich, 1 
mM for 16 hours), irradiated with 10 J/m2 UV-C or 
serum-starved for 72 hours, followed by staining with 
either with trypan blue, Annexin-V, anti-activated 
Caspase-3 or by Tunel assay. Senescence: cells were 
stained at the indicated times after plating using a 
Senescence Cells Histochemical Staining Kit (Sigma 
Aldrich), according to manufacturer’s protocol. ROS 
measurement: equal numbers of cells were incubated 
with 5 μM H2DCFDA (Molecular Probes, Invitrogen) 
for 30 min at room temperature and analyzed by flow 
cytometry. 
 
Microarray analysis. Micro array data are accessible 
from the Gene Expression Omnibus 
(http://www.ncbi.nih.gov/geo/) under accession 
GSE21507. 
 
Total RNA was prepared from sub-confluent MEF cells 
derived from three independent embryos per genotype. 
Samples were analyzed using the MouseWG-6 v 1.1 
Expression BeadChip (Illumina, San Diego CA, USA) 
as previously described [31]. Briefly, RNA was first 
reverse transcribed using oligo (dT) primers to 
synthesise first strand cDNA, followed by second strand 
synthesis. cDNA was then purified to remove salt, 
RNA, enzymes, and excess primers.  Subsequent in 
vitro transcription synthesised biotin-labelled cRNA, 
which was further purified and then hybridised to the 
array chip.  
 
Real Time-PCR. Total RNA was prepared with the 
PureLink Micro-to-Midi total RNA Purification System 
(Invitrogen). qRT-PCR reactions were performed as 
previously described [44], using the Universal Probe 
Library system (Roche Italia, Monza, Italy). The 18S 
rRNA pre-developed TaqMan assay (Applied 
Biosystems) was used as an internal control. For 
primers and probes see Supplementary Information. 
 
Lentiviral infection. pLKO vectors carrying either 
scrambled or shRNA-HIF-1α sequences (Open 
Biosystems, Huntsville AL, USA) were packaged by 
transfecting 293T cells and used to infect cells for 24 
hours, followed by puromycin selection for 48 hours. 
 
FACS Analysis. H2DCFDA and Annexin-V emission 
were detected in the green channel (525 nm) and 
propidium iodide in the red channel (575 nm) following 
excitation by a 488 nm laser on a FACS Calibur 
cytometer (Beckton, Dickinson and Company, Franklin 
Lakes NJ, USA). 
 
Western blot. Total, nuclear, mitochondrial and 
cytosolic protein extracts, obtained as previously 
described [45] were fractionated on SDS-PAGE and 
transferred to a polyvinylidene difluoride membrane 
(Millipore, Billerica MA, USA). 
 
Glucose and lactate measurements. Glucose or lactate 
were measured in cell supernatants 3 hours after 
changing medium using a Glucose Assay Kit (Sigma 
Aldrich) or a Lactate Colorimetric Assay Kit (Abcam). 
Data were normalized to final cell counts. Glucose 
intake was calculated as the difference in glucose 
concentration between fresh medium and supernatant.  
 
Glucose dependence.  For glucose deprivation, cells 
were cultivated in DMEM containing 0 g/l of glucose 
and 3% FBS for 48 hours, then stained with Trypan 
Blue (Invitrogen). For 2-deoxyglucose (2-DG) 
treatment, cells were treated with 1.5 mg/ml (MEFs) or 
1 mg/ml (MDA-MB468) of 2-DG (Sigma Aldrich) for 
48 hours, then stained with propidium iodide and/or 
AnnexinV followed by flow cytometry analysis.  
 
Calcium and ATP measurements. Cells were grown on 
glass coverslips at 50% confluence. For Ca2+ 
measurements,  cells were infected with the adenovirus 
expressing the appropriate aequorin chimera as 
previously described [46]. Measurements were carried 
out in KRB (125 mM NaCl, 5 mM KCl, 1 mM MgSO4, 
1 mM Na2HPO4, 5.5 mM glucose, 20 mM NaHCO3, 
2 mM l-glutamine and 20 mM HEPES pH 7.4, 
supplemented with 1 mM CaCl2). Agonists and other 
drugs were added to the same medium. Cells were lysed 
with 100 µM digitonin in a hypotonic Ca2+-rich solution 
(10 mM CaCl2 in H2O), thus discharging the remaining 
aequorin pool. The light signal was collected and 
calibrated into [Ca2+] values, as previously described 
[46]. 
 
For measuring mitochondrial ATP, MEFs were 
transfected with mitochondrial luciferase (mtLuc), and 
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luminescence measured after 36 hours as previously 
described [47]. Cells were constantly perfused with a 
modified KRB containing 20 μM luciferin (Sigma 
Aldrich).  
 
Immunofluorescence. Cells plated on glass coverslips 
were washed in PBS, fixed in 4% paraformaldehyde, 
quenched with 50 mmol/L ammonium chloride, 
permeabilized with 0.3% Triton X-100 in PBS, 
saturated with 3% bovine serum albumin, and incubated 
with primary antibodies at room temperature for 1 h, 
followed by fluorescein-labeled secondary antibodies 
(Sigma Aldrich) and then by Hoechst-dye. Tunel assay 
(Roche Diagnostic Corp., Indianapolis IN, USA) was 
performed according to manufacturer’s protocol. An 
Axiovert 200M Zeiss microscope or the Axio-Observer-
Z1 Zeiss microscope with the ApoTome system for 
optical sectioning were used. Images were acquired 
with MetaMorph software (Molecular Devices, 
Toronto, Canada) or the AxioVision release 4.6.3 
software (Carl Zeiss, Inc., Oberkochen, Germany), 
respectively. 
 
PDH activity. 106 cells were plated on a 100*15 mm 
dish and detached after 24 hours. PDH activity was 
measured using the PDH mitoprofile kit (Invitrogen) 
according to manufacturer’s protocol. 
 
Immunoprecipitation. Freshly prepared pre-cleared 
lysates were incubated O/N at 4°C with anti-HIF-1α 
antibody and 20 µl of protein G-Sepharose beads (Ge 
Healthcare Bio-Science, Uppsala, Sweden). 
Immunoprecipitated proteins were boiled in 1x 
Laemmli  buffer for 5 min.  
 
Mitochondrial membrane potential (mtΔΨ). Cells 
grown in 24-well plates were incubated with 10 µM JC1 
(5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-enzimidazolyl-
carbocyanine iodide) in PBS containing 5 mM glucose 
for 10 min at 37°C followed by fluorescence recording 
in a microplate reader (Infinite M200, Tecan, Austria) at 
485 nm excitation/520 nm emission and 535 nm 
excitation/635 nm emission wavelengths. 
 
Respiratory chain activity. MEFs grown in 24-well 
plates were washed with PBS, PBS containing 5 mM 
glucose and 6 µM resazurine was added and 
fluorescence was recorded immediately in a microplate 
reader (Infinite M200, Tecan, Austria) at 510 nm 
excitation and 595 nm emission wavelengths. For 
control of the threshold activity, cells were preincubated 
for 15 min with 2 µM KCN in complete medium and 
measurements were performed as described above but 
in PBS containing 2 µM KCN. The activity values were 
normalized to mg of protein.  
ATP/ADP ratio. ADP and ATP levels were measured 
using an ADP/ATP ratio kit (Abcam).  
 
Sub-cellular fractionation. Sub-cellular fractionation 
was performed essentially as described [48,49]. Briefly, 
cells (109) were harvested, washed in PBS, pelleted, 
resuspended in homogenization buffer (0.25 M sucrose 
and 10 mM Hepes pH 7.4) and gently disrupted by 
dounce homogenization. Upon gentle centrifugation to 
remove cellular debris and nuclei, the supernatant was 
centrifuged at 10.300 x g for 10 min to pellet crude 
mitochondria, which were resuspended in isolation 
medium (250 mM mannitol, 5 mM Hepes pH 7.4, 0.5 
mM EGTA). 
 
Microscopic analysis of mitochondrial structure. 
Mitochondrial structure was studied after loading 10nM 
of Tetramethyl rhodamine methyl ester (TMRM). 
Images were recorded using a digital imaging system 
based on a Zeiss Axiovert 200 fluorescence microscope 
equipped with a back-illuminated CCD camera  (Roper 
Scientific, USA), excitation and emission filter wheels 
(Sutter Instrument Company, USA) and piezoelectric 
motoring of the z stage (Physik Instrumente, GmbH & 
Co., Germany).  The data were acquired and processed 
using the MetaFluor analyzing program 
(Universal Imaging Corporation, USA). 
 
Small animal PET. PET images were acquired on the 
positron emission tomograph for small animals YAP-
(S)PET system [50]. Mice were fasted overnight before 
PET acquisition, anesthetized by inhalation of 2% of 
isofluorane and intravenously injected with 350µCi±50 
of [18F]fluorodeoxyglucose ([18F]FDG) in a 0.15-ml 
volume. The residual dose in the syringe was measured 
to verify the effective injected dose. The tumour was 
centred on the field of view of the tomograph and a 
static acquisition started after 45 minutes of uptake. A 
3D data acquisition mode and an expectation 
maximization (EM) algorithm with 30 iterations for 
image reconstruction were used, the resulting voxel size 
was 0.5×0.5×2mm3. No corrections were made for 
attenuation and scatter. The images were visualized 
with dedicated software in the three planes (transaxial, 
sagittal, and coronal). Quantitative image analysis of 
tracer uptake was evaluated by drawing region of 
interest (ROI) of tumour on the transaxial images. 
18F]FDG uptake was quantified as standardized uptake 
values (SUV) and as percentage of the injected dose per 
gram of tissue (%ID/g). 
 
Statistical analysis. An unpaired t test was used to 
calculate a P value for two groups, while a P value on a 
response affected by two factors was calculated with a 
two-way ANOVA [51].  
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subjected  to serum‐starvation  for 72 hours and  then stained with a TUNEL assay  (B) or with an antibody against activated
caspase‐3 (C). (B) Arrows indicate TUNEL‐positive cells. Nuclei are shown in blue. Numbers represent the mean percentage of
positive cells ± s.e.m. of three independent samples per genotype. (C) Numbers represent the percentage (mean ± s.e.m.) of
positive  cells  from  three  independent  samples  per  genotype.  *,  p  <  0.01.  (D)  Menadione‐induced  apoptosis.  Cells were
treated with 7,5 μM Menadione for 24 hours. (E) UV‐induced apoptosis. Cells were treated with UV light (10 j/m2) and stained
for  Annexin  V  after  24  hours.  (D,E)  Data  represent  the  percentage  of  Annexin  V  positive  cells  (mean  ±  s.e.m.)  of  three
independent samples per genotype. *, p < 0.01. Empty bars or filled bars, Stat3WT/WT or Stat3C/C MEFs. 
  








































































































MEFs  respectively,  either  silenced  or  not  for  HIF‐1α  (sh‐HIF‐1α),  represent mean  values  ±  s.e.m.  of  three  independent
experiments.  *,  p  ≤  0,01.  ATP‐5L,  ATP  synthase,  H+  transporting,  mitochondrial  F0  complex,  subunit  G;  FH,  fumarate
hydratase; MRPL39, 39S ribosomal protein L39, mitochondrial. 
Supplementary Figure S3. The glycolytic phenotype
specifically depends on  Stat3 activity.  (A‐C)  Inhibition
of  the  PI3‐K/AKT  pathway.  Cells were  treated  for  48
hours  with  the  PI3  Kinase  inhibitor  Ly294002.  (A)
Western  blot  analysis  on  total  protein  extracts
showing  decreased  P‐AKT  upon  Ly294002  treatment.
The expression of Hif‐1α and Pdk1 mRNAs (B) and the
accumulation  of  lactate  (C)  are  not  affected  by
Ly294002  treatment.  (D,E)  Similar  Hif‐1α  and  Pdk1
mRNAs  levels  and  lactate  accumulation  in  Stat3+/+ or
Stat3‐/‐  3T3 MEFs. Data  are  shown  as mean  values  ±
s.e.m. of three samples per genotype. 
  




Supplementary  Figure  S4.  Stat3‐dependent  glycolytic metabolism  and mitochondrial  activity  in  tumour  cell  lines.  (A)  The
STAT3‐dependent MDA‐MB468, SKBR3, DU145 and the STAT3‐independent T47D human tumour cells were either treated or
not with the S3I STAT3 inhibitor for 12 hours followed by the analysis of total and Y705 phosphorylated STAT3 by Western‐
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SUPPLEMENTARY MATERIALS AND 
METHODS 
 
Primer sequences and probes used for Taqman PCR: 
mmu HIF-1α upper, 5’-gcactagacaaagttcacctgaga-3’  
mmu HIF-1α lower, 5’-cgctatccacatcaaagcaa-3’, Probe: 
#95 
mmu PDK-1 upper, 5’-gttgaaacgtcccgtgct-3’ 
mmu PDK-1 lower, 5’-gcgtgatatgggcaatcc-3’, Probe: 
#20 
mmu GLUT-1 upper, 5’-atggatcccagcagcaag-3’ 
mmu GLUT-1 lower, 5’-ccagtgttatagccgaactgc-3’, 
Probe: #52 
mmu PFK-L upper, 5’-ccatggacgaggagaggtt-3’ 
mmu PFK-L lower, 5’-tccagttgttctcaaagctcct-3’, Probe: 
#42 
mmu ENO-1 upper, 5’-gaggcgcttagtgctgct-3’ 
mmu ENO-1 lower, 5’-agaatagacatggcgaatttctg-3’, 
Probe: #91 
mmu OSM-R upper, 5’- ccaaaaagagttcagcacacc -3’ 
mmu OSM-R lower, 5’- ccgaccacacttgtctccat -3’, Probe: 
#32 
mmu PDGFRa upper, 5’-gtcgttgacctgcagtgga-3’ 
mmu PDGFRa lower, 5’-ccagcatggtgatacctttgt-3’, 
Probe: #80 
mmu SOCS-3 upper, 5’-atttcgcttcgggactagc-3’ 
mmu SOCS-3 lower, 5’-aacttgctgtgggtgaccat-3’, Probe: 
#83 
mmu ATP-5L upper, 5’-aaggaagctgtgctgaatgg-3’ 
mmu ATP-5L lower, 5’-atgccacgtttgcctatga-3’, Probe: 
#42 
mmu FH-1 upper, 5’-gcaccccaatgatcatgtta-3’ 
mmu FH-1 lower, 5’-cattgctgtgggaaaggtg -3’, Probe: 
#106 
mmu NDUFB4 upper, 5’-agggtggtgaagtggaagag-3’ 
mmu NDUFB4 lower, 5’-tggccacttccactggtta-3’, Probe: 
#31 
mmu NDUFA6 upper, 5’-cccactcccaagaactcact-3’ 
mmu NDUFA6 lower, 5’-tggataagtctttcctttctgtcc-3’, 
Probe: #17 
hsa HIF-1α upper, 5’-ggttcactttttcaagcagtagg-3’ 
hsa HIF-1α lower, 5’-tggtaatccactttcatccattg-3’, Probe: 
#3 
hsa PDK-1 upper, 5’-gctgggtaatgaggatttgact-3’ 
hsa PDK-1 lower, 5’-aagtctgtcaattttcctcaaagg-3’, Probe: 
#10 
hsa ENO-1 upper, 5’-gctccgggacaatgataaga-3’ 
hsa ENO-1 lower, 5’-tgatgtgctcaacagccttt-3’, Probe: 
#60 
 
Antibodies. Rabbit polyclonal against p-Stat3, p-Akt 
and Caspase-3 (Cell Signaling Technology, Danvers 
MA, USA), Stat3 and Actin (Santa Cruz Biotechnology, 
Santa Cruz CA, USA), Vdac-1 (Abcam, Cambridge, 
UK). Mouse monoclonal against Hif-1α (Novus 
Biologicals, Littleton CO, USA), Sod2 (Abcam) and β-
Tubulin (Santa Cruz Biotechnology). Mouse 
monoclonal against Akt was generated in house by 
immunization with a MBP-Akt fusion protein and 
purified against the recombinant protein. The 
MitoProfile total OXPHOS rodent WB Antibody 
Cocktail (Mitosciences, Eugene OR, USA) was used for 
mitochondrial complexes. 
 
In vivo model. 8 Female mice 5 to 7 weeks of age were 
s.c. implanted in CD-1 mice (Charles River 
Laboratories, Inc.) with MDA-MB468. Cells were 
harvested using trypsin and washed with PBS. 107 Cells 
were resuspended in 200 μL PBS and injected s.c. into 
the left flank of mice. 14 days after the inoculation of 
tumour cells, mice were randomly divided in two 
groups and the first PET acquisition was performed. 
Subsequently the first group (n=5) received in the tail 
vein a 5 mg/kg of S3I three time per week for 2 
consecutive weeks; the second group (n=3) was not 
treated. All mice were monitored two times weekly for 
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